Reviews & Analysis

To accelerate the development of T cell–based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day’s workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed — with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.

In the spring of 2020, a series of reports from Europe and the USA described clusters of children and adolescents presenting with a life-threatening, hyperinflammatory syndrome — called ‘multi-system inflammatory syndrome in children’ (MIS-C) — that was seemingly linked to prior exposure to the coronavirus SARS-CoV-2. In June 2020, the US National Institutes of Health convened a workshop of immunologists and clinicians to discuss emerging knowledge and identify key questions surrounding MIS-C, with a focus on innate and adaptive immunity, genetics and epigenetics. This Meeting Report describes the main findings from the workshop.

In 1978, the birth of the first baby through in vitro fertilization resulted in an explosion of new techniques that are now widely used in reproductive medicine and biology around the world. With these advances have also come many concerns for the safety of these techniques. In addition, even newer technologies are on the horizon, such as cloning and the production/use of stem cells. The 18th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), held in Vienna from 30 June to 3 July 2002, provided a forum for discussion of these and other relevant topics.